These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 37544876)
41. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade. Grunke M; Schulze-Koops H Ann Rheum Dis; 2006 Apr; 65(4):555-6. PubMed ID: 16531556 [No Abstract] [Full Text] [Related]
42. Production and characterization of monoclonal antibodies against recombinant human tumor necrosis factor/cachectin. Liang CM; Liang SM; Jost T; Sand A; Dougas I; Allet B Biochem Biophys Res Commun; 1986 Jun; 137(2):847-54. PubMed ID: 3729942 [TBL] [Abstract][Full Text] [Related]
43. Membrane-bound tumour necrosis factor alpha: immunocytochemical and ultrastructural studies of human monocytes and monocytic cell line and its induction by tumour cells in vitro. Mytar B; Stachura J; Kielar B; Stec WJ; Zembala M Patol Pol; 1992; 43(2):51-4. PubMed ID: 1296176 [TBL] [Abstract][Full Text] [Related]
44. Response to Tumor Necrosis Factor-α Blocker in Patients With Ankylosing Spondylitis: Methodologic Issues for Clinical Outcome Prediction. Sabour S AJR Am J Roentgenol; 2020 Oct; 215(4):W46. PubMed ID: 32960083 [No Abstract] [Full Text] [Related]
46. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies. Ebert EC; Das KM; Mehta V; Rezac C Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498 [TBL] [Abstract][Full Text] [Related]
48. Does anti-tumour necrosis factor alpha treatment modify the tuberculin PPD response? Joven BE; Almodóvar R; Galindo M; Mateo I; Pablos JL Ann Rheum Dis; 2006 May; 65(5):699. PubMed ID: 16611876 [No Abstract] [Full Text] [Related]
49. Reply to "Response to Tumor Necrosis Factor-α Blocker in Patients With Ankylosing Spondylitis: Methodologic Issues for Clinical Outcome Prediction". Kim K; Kim SJ AJR Am J Roentgenol; 2020 Oct; 215(4):W47. PubMed ID: 32960086 [No Abstract] [Full Text] [Related]
51. Prolonged response to anti-tumour necrosis factor treatment with adalimumab (Humira) in relapsing polychondritis complicated by aortitis. Seymour MW; Home DM; Williams RO; Allard SA Rheumatology (Oxford); 2007 Nov; 46(11):1738-9. PubMed ID: 17933796 [No Abstract] [Full Text] [Related]
52. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure. Macaluso FS; Criscuoli V; Orlando E; Rizzuto G; Renna S; Cottone M; Orlando A Aliment Pharmacol Ther; 2016 May; 43(9):1019-20. PubMed ID: 27040168 [No Abstract] [Full Text] [Related]
53. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease. Vadikolias K; Kouklakis G; Heliopoulos I; Argyropoulou P; Papanas N; Tzilonidou M; Prassopoulos P; Piperidou H Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):159-62. PubMed ID: 17273002 [TBL] [Abstract][Full Text] [Related]
54. Treating rheumatoid arthritis with tumour necrosis factor alpha blockade. Emery P; Buch M BMJ; 2002 Feb; 324(7333):312-3. PubMed ID: 11834544 [No Abstract] [Full Text] [Related]
55. Induction of manic switch by the tumour necrosis factor-alpha antagonist infliximab. Elisa B; Beny L Psychiatry Clin Neurosci; 2010 Aug; 64(4):442-3. PubMed ID: 20653912 [No Abstract] [Full Text] [Related]
56. Anti-tumour necrosis factor therapy in ankylosing spondylitis. A need for guidelines. Kassimos DG; Garyfallos A; Delamere J; Whallett A; Kitas GD Rheumatology (Oxford); 2003 Mar; 42(3):490. PubMed ID: 12626807 [No Abstract] [Full Text] [Related]
57. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Elliott MJ; Maini RN; Feldmann M; Long-Fox A; Charles P; Bijl H; Woody JN Lancet; 1994 Oct; 344(8930):1125-7. PubMed ID: 7934495 [TBL] [Abstract][Full Text] [Related]